Genmab A/S

GMAB • Biotechnology

$39.43

▲ +0.36 (+0.92%)

Current price

EarningsLatest report: Mar 31, 2026

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$25.18B

Growth

—

Cash Flow

5/5

Trend

Stable

Evidence

Stable or improving margins · 25.9%Positive free cash flow · 1.85Consistent free cash flow · 5/5Reasonable earnings multiple · 19.86Healthy liquidity · 2.02

Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 7, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$39.43

Change0.92%

Shares Out638.55M

Market Cap$25.18B

Enterprise Value$28.88B

52W Range20.23 - 35.43

Beta0.68

P/E30.67

P/S6.45

P/B4.43

P/FCF28.90

EV/Sales7.40

Price$39.43

Change0.92%

Shares Out638.55M

Market Cap$25.18B

Enterprise Value$28.88B

52W Range20.23 - 35.43

Beta0.68

P/E30.67

P/S6.45

P/B4.43

P/FCF28.90

EV/Sales7.40

EV/EBITDA20.35

EV/FCF33.15

Earnings Yield3.26%

FCF Yield3.46%

Dividend Yield0.00%

Gross Margin91.69%

Oper. Margin33.60%

Profit Margin25.89%

Debt/Eq0.93

Current Ratio2.02

Quick Ratio2.01

Target$44.20

Target Upside12.10%

Target Median$42.00

Target Range38.00 - 58.00

Volume2.01M

Avg Volume1.79M

EPS Surprise0.00

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

77/100

Financial Strength

Debt, cash, stability

88/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

68/100

Why this score▼

Stable or improving margins · 25.9%Positive free cash flow · 1.85Consistent free cash flow · 5/5Reasonable earnings multiple · 19.86Healthy liquidity · 2.02Negative growth trend

Analyst view

Analyst sentiment and price target

GMAB

Analyst sentiment

Based on 18 analyst votes · 2026-10-20

83/100

Bullish

Hold

Bearish

Price Target

2026-08-07

Low

$32.00

Mean

$39.08

Median

$40.00

High

$43.00

Company Overview

IPO: 6/1/2009

Industry: Biotechnology

P/B i: 4.43

Debt / Equity i: 0.93

Operating Margin: 33.60%

Net Margin: 25.89%

ROE i: -

ROIC: -

Financial Health

Score18 / 20

Debt / Equity: 0.93

Current Ratio: 2.02

Quick Ratio: 2.01

Status: Strong

🧾

No insider activity

No recent insider transactions available.

About the Company

Genmab A/S

Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. The company's commercialized portfolio includes several key products: DARZALEX (daratumumab), a human monoclonal antibody for multiple myeloma (MM), non-MM blood cancers, and AL amyloidosis; teprotumumab, indicated for thyroid eye disease; ofatumumab, another human monoclonal antibody used in chronic lymphocytic leukemia (CLL) and multiple sclerosis; Amivantamab, for advanced or metastatic gastric or esophageal cancer and non-small cell lung cancer (NSCLC); and tisotumab vedotin, which targets cervical, ovarian, and solid tumors. Genmab maintains a robust pipeline of investigational medicines. These include GEN1047; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB, both developed for solid tumors; Epcoritamab, in development for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37, aimed at hematological malignancies. Furthermore, the company has several products in Phase 2 clinical trials: Teclistamab for vaso-occlusive crises; Camidanlumab tesirine for Hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 for MM; PRV-015 for celiac disease; Mim8 for haemophilia A; and Lu AF82422 for multiple system atrophy disease. In addition to its clinical programs, Genmab is advancing approximately 20 active pre-clinical programs. Genmab fosters strategic collaborations to further its research and development efforts. It holds a commercial license and co-development agreement with Seagen Inc. for tisotumab vedotin. The company also partners with CureVac AG on the research and development of differentiated mRNA-based antibody products and with AbbVie for the development of epcoritamab. Further alliances include BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc.

Source - link

Peers

DGX EXEL ILMN INCY ROIV RPRX SMMT THC UTHR ZBH

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Critical Analysis: Genmab A/S (NASDAQ:GMAB) versus Cardio Diagnostics (NASDAQ:CDIO)

Genmab A/S (NASDAQ: GMAB - Get Free Report) and Cardio Diagnostics (NASDAQ: CDIO - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, risk and earnings. Volatility and Risk Genmab A/S has a beta

Defense World

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026

Company Announcement Net sales of DARZALEX ® in the third quarter of 2026 totaled USD 4,239 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; October 13, 2026 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO ® in the U.S. ), as reported by J&J were USD 4,239 million in the third quarter of 2026. Net trade sales were USD 2,528 million in the U.S. and USD 1,711 million in the rest of the world.

GlobeNewsWire

Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members

Company Announcement COPENHAGEN, Denmark; October 7, 2026 – Genmab A/S (Nasdaq: GMAB) Today, Genmab A/S held an Extraordinary General Meeting.At the Extraordinary General Meeting the proposal from the Board of Directors on remuneration of the Board of Directors for 2026, including share-based remuneration in the form of restricted stock units, was approved.

GlobeNewsWire

Genmab: Epkinly Shines In Phase 3 DLBCL Trial

Genmab delivered strong topline results for Epkinly in frontline DLBCL, showing a 51% reduction in risk of progression or death. Epkinly's efficacy notably exceeds Roche's Polivy in similar settings, positioning GMAB as a potential market leader among T-cell engagers. Frontline DLBCL represents the key growth driver for Epkinly, and I see upside to the company's $3 billion+ peak sales guidance based on better-than-expected treatment effect.

Seeking Alpha

AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL

ABBV's epcoritamab plus R-CHOP cut progression or death risk by 51% in frontline DLBCL, meeting the phase III study's PFS goal.

Zacks Investment Research

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-07	0.15	0.15	0
2026-02-17	0.46	0.05	-0.41
2025-11-06	0.48	0.65	0.17
2025-08-07	0.39	0.54	0.15
2025-05-08	0.23	0.31	0.08
2025-02-12	0.28	0.57	0.29
2024-11-06	0.35	0.29	-0.06
2024-08-08	0.29	0.22	-0.07
2024-05-02	0.16	0.16	0
2024-02-14	0.34	0.36	0.02
2023-11-07	3.14	0.47	-2.67
2023-08-03	2.18	0.3	-1.88